These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34163726)

  • 21. Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers.
    Arezumand R; Alibakhshi A; Ranjbari J; Ramazani A; Muyldermans S
    Front Immunol; 2017; 8():1746. PubMed ID: 29276515
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Kazemi-Lomedasht F; Pooshang-Bagheri K; Habibi-Anbouhi M; Hajizadeh-Safar E; Shahbazzadeh D; Mirzahosseini H; Behdani M
    Iran J Basic Med Sci; 2017 May; 20(5):489-496. PubMed ID: 28656083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generation, biochemical characterizations and validation of potent nanobodies derived from alpaca specific for human receptor of advanced glycation end product.
    Mohammed A; Zeng W; Mengist HM; Kombe Kombe AJ; Ou H; Yang Y; Dan Z; Xu Z; Ma H; Jin T
    Biochem Biophys Res Commun; 2021 Dec; 581():38-45. PubMed ID: 34653677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Agonistic nanobodies and antibodies to human VISTA.
    Ma YV; Sparkes A; Romão E; Saha S; Gariépy J
    MAbs; 2021; 13(1):2003281. PubMed ID: 34818120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dinitrophenol-mediated modulation of an anti-PD-L1 VHH for Fc-dependent effector functions and prolonged serum half-life.
    Liu J; Hong H; Shi J; Xie Y; Lu Z; Liu Z; Zhou Z; Bian Z; Huang Z; Wu Z
    Eur J Pharm Sci; 2021 Oct; 165():105941. PubMed ID: 34256102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.
    Monnet C; Jorieux S; Souyris N; Zaki O; Jacquet A; Fournier N; Crozet F; de Romeuf C; Bouayadi K; Urbain R; Behrens CK; Mondon P; Fontayne A
    MAbs; 2014; 6(2):422-36. PubMed ID: 24492301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
    Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
    J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing.
    Brandsma AM; Ten Broeke T; Nederend M; Meulenbroek LA; van Tetering G; Meyer S; Jansen JH; Beltrán Buitrago MA; Nagelkerke SQ; Németh I; Ubink R; Rouwendal G; Lohse S; Valerius T; Leusen JH; Boross P
    Cancer Immunol Res; 2015 Dec; 3(12):1316-24. PubMed ID: 26407589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy.
    Babamohamadi M; Mohammadi N; Faryadi E; Haddadi M; Merati A; Ghobadinezhad F; Amirian R; Izadi Z; Hadjati J
    Cell Death Dis; 2024 Jan; 15(1):17. PubMed ID: 38191571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-EGF nanobodies enhance the antitumoral effect of osimertinib and overcome resistance in non-small cell lung cancer (NSCLC) cellular models.
    Guardiola S; Sánchez-Navarro M; Rosell R; Giralt E; Codony-Servat J
    Med Oncol; 2022 Sep; 39(12):195. PubMed ID: 36071367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nanobodies: A Game-Changer in Cell-Mediated Immunotherapy for Cancer.
    Mustafa MI; Mohammed A
    SLAS Discov; 2023 Dec; 28(8):358-364. PubMed ID: 37634615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanobody-Engineered Natural Killer Cell Conjugates for Solid Tumor Adoptive Immunotherapy.
    Gong L; Li Y; Cui K; Chen Y; Hong H; Li J; Li D; Yin Y; Wu Z; Huang Z
    Small; 2021 Nov; 17(45):e2103463. PubMed ID: 34761524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
    Ashraf Y; Mansouri H; Laurent-Matha V; Alcaraz LB; Roger P; Guiu S; Derocq D; Robin G; Michaud HA; Delpech H; Jarlier M; Pugnière M; Robert B; Puel A; Martin L; Landomiel F; Bourquard T; Achour O; Fruitier-Arnaudin I; Pichard A; Deshayes E; Turtoi A; Poupon A; Simony-Lafontaine J; Boissière-Michot F; Pirot N; Bernex F; Jacot W; du Manoir S; Theillet C; Pouget JP; Navarro-Teulon I; Bonnefoy N; Pèlegrin A; Chardès T; Martineau P; Liaudet-Coopman E
    J Immunother Cancer; 2019 Feb; 7(1):29. PubMed ID: 30717773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments.
    Moreno-Vicente J; Willoughby JE; Taylor MC; Booth SG; English VL; Williams EL; Penfold CA; Mockridge CI; Inzhelevskaya T; Kim J; Chan HTC; Cragg MS; Gray JC; Beers SA
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy.
    Nikkhoi SK; Li G; Eleya S; Yang G; Vandavasi VG; Hatefi A
    Front Immunol; 2022; 13():1039969. PubMed ID: 36685519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification and Characterization of Specific Nanobodies against Trop-2 for Tumor Targeting.
    Hu Y; Wang Y; Lin J; Wu S; Lv H; Ji X; Wang S
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanobodies with cross-neutralizing activity provide prominent therapeutic efficacy in mild and severe COVID-19 rodent models.
    Han Q; Wang S; Wang Z; Zhang C; Wang X; Feng N; Wang T; Zhao Y; Chi H; Yan F; Xia X
    Virol Sin; 2023 Oct; 38(5):787-800. PubMed ID: 37423308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanobodies as versatile tools: A focus on targeted tumor therapy, tumor imaging and diagnostics.
    Al-Baradie RS
    Hum Antibodies; 2020; 28(4):259-272. PubMed ID: 32831197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dinitrophenol-Hyaluronan Conjugates as Multivalent Antibody-Recruiting Glycopolymers for Targeted Cancer Immunotherapy.
    Lin H; Zhou K; Li D; Hong H; Xie Y; Gong L; Shen Y; Zhou Z; Shi J; Wu Z
    ChemMedChem; 2021 Oct; 16(19):2960-2968. PubMed ID: 34235861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.